Objective: Schizophrenia is treated with medications that raise serum anticholinergic activity
and are known to adversely affect cognition. The authors examined the relationship between …

Background Cognitive deficits are prevalent in people with schizophrenia and associated
with functional impairments. In addition to antipsychotics, pharmacotherapy in schizophrenia …

Background Patients with psychotic disorders are often treated with numerous medications,
many of which have anticholinergic activity. We assessed cognition in relation to the …

Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Many patients with schizophrenia show cognitive impairment. There is evidence that,
beyond a certain dose of antipsychotic medication, the antipsychotic daily dose (ADD) may …

Antipsychotic polypharmacy and excessive dosing still prevail worldwide in the treatment of
schizophrenia, while their possible association with cognitive function has not well been …

OBJECTIVE: The authors' goals were 1) to establish a clinically useful standard index of the
relative anticholinergic potency of psychiatric medications; 2) to determine which cognitive …

Valid cognitive deficits in schizophrenia are now well characterised: general poor
performance with disproportionate deficits in aspects of memory and executive function …

The aim of this study was to compare cognitive performance between schizophrenia patients
with and without treatment resistance (TRS and non-TRS patients) taking into account …

We evaluated the effect of antipsychotic dose-reduction on the neurocognitive function of 17
schizophrenic patients (11 male and 6 female, mean age= 42.4±11.3) who have been taking …